OMED Health starts pilot for staff at Aviva

OMED Health has started a pilot study as part of its longstanding collaboration with Aviva, the UK’s leading diversified insurer.

The pilot, involving 75 Aviva employees, intends to demonstrate the value of the OMED Health solution in a workplace setting by addressing the significant impact of gastrointestinal conditions on employee health and workplace productivity.

OMED Health was founded in 2022 and is a division of Owlstone Medical, the world leader in breath analysis based on Cambridge Science Park.

Ant Barker, director of venture capital at Aviva Investors, said: “As well as being an investor in Owlstone, Aviva is committed to supporting the wellbeing of our employees and we’re pleased to offer this unique opportunity for our colleagues to play a role in medical developments.

“Owlstone’s innovative approach has the potential to transform how these conditions are understood and managed, and we’re excited to support their journey through this pilot initiative.”

Billy Boyle, co-founder and CEO at Owlstone Medical, said: “We intend for the OMED solution to become part of the standard of care, either from ourselves or through license partners, and are grateful to Aviva for the support and funding provided for this study which will help us to advance towards this goal.”

The study is expected to be completed within six months.